Cancer Diagnosis News
-
National Cancer Prevention Month and Protecting Workers and Building Occupants in Puerto Rico from Carcinogens
The International Agency for Research on Cancer reports that as recently as 2020, there were over 13,000 new cases of cancer in Puerto Rico. Tragically, there were also more than 5,500 deaths due to cancer in Puerto Rico that year alone. The American Association for Cancer Research has reported that more than 40% of all diagnosed cancers in the U.S. can be attributed to preventable causes. ...
-
Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...
-
CD Genomics Unveils Cutting-Edge CRISPR Screen Sequencing Technology
CD Genomics, a distinguished leader in genomics and sequencing services, has proudly unveiled its groundbreaking CRISPR Screen Sequencing technology. This innovative solution promises to expedite discoveries, facilitate target identification, and optimize drug development pipelines within the biotechnology and pharmaceutical industries. CRISPR Screen Sequencing, a genome-wide screening ...
By CD Genomics
-
NICE Irreversible Electroporation for Treating Prostate Cancer Announcement
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute ...
-
Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer progresses novel research ...
By Bayer AG
-
Bayer expands global clinical program for darolutamide in prostate cancer
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to metastatic stage Bayer further expands ...
By Bayer AG
-
Nubeqa (darolutamide) approved for additional prostate cancer indication in China
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with docetaxel for the ...
By Bayer AG
-
Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer
European Commission granted approval of Nubeqa (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) Approval is based on Phase III ARASENS trial data The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation ...
By Bayer AG
-
Nubeqa approved for additional indication in Japan
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer New approval based on data from the pivotal Phase III ARASENS trial The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate ...
By Bayer AG
-
How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis
Dr. Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. Confidence in finding lifesaving cures is at an all-time high among medical researchers who work tirelessly for a solution. Astounding ...
-
New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various types of metastatic disease burden and risk, compared to ADT with docetaxel alone Favorable safety profile of darolutamide plus ADT in combination ...
By Bayer AG
-
National Cancer Prevention Month in Puerto Rico and Resources to Protect Workers and Building Occupants from Carcinogens
While cancer mortality has gradually declined over the past several decades in Puerto Rico, there are still more than 10,000 new cases of cancer and over 5,000 deaths each year on the islands. Nationwide, the National Cancer Institute estimates there were over 1,918,000 new cases of cancer diagnosed in 2022 and more than 609,000 people died from cancer that year alone. There are over 100 types ...
-
BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
-
CD Genomics Optimized Cancer Hotspot Panel Sequencing Service for Cancer-Related Research
Based on rich experience in genomic analysis, CD Genomics has developed a specialized platform for targeted sequencing of cancer-related genes to accelerate research on disease pathogenesis, disease identification, biomarker discovery, targeted drug development, etc. The company has optimized its Cancer Hotspot Panel Sequencing service to meet the most challenging research process. Cancer is ...
By CD Genomics
-
CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel alone, with similar overall rates of adverse events between study arms European Commission decision on granting a marketing authorization is anticipated within ...
By Bayer AG
-
4D Path Closes Latest Funding Round to Advance New Approach to Precise and Accelerated Cancer Diagnosis, Bringing Total to $6.4M
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology ...
By 4D Path Inc.
-
Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...
-
Cartherics granted first patent in China for multiple development candidates
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent ...
-
Unbiased gene fusion analysis required in future cancer diagnostics
Today about 20 cancer treatments approved by FDA and EMA are directed towards specific gene fusions, and the number of drugs available is growing annually. The increased importance of gene fusions in oncology is driving demand from diagnostic laboratories for scalable analytical solutions. RNA can be used to analyze gene fusions. Moreover, while DNA is largely identical in all cells, RNA ...
By Qlucore AB
-
Antengene Announces NDA Submission for XPOVIO in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you